Lamivudine/nevirapine/zidovudine

Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination medication used to treat HIV/AIDS.[2] It contains lamivudine, nevirapine, and zidovudine.[2] It is either used by itself or along with other antiretrovirals.[2] It is a recommended treatment in those who are pregnant.[2] It is taken by mouth twice a day.[2]

Lamivudine/nevirapine/zidovudine
Combination of
Lamivudinenucleoside reverse transcriptase inhibitor
Nevirapinenon-nucleoside reverse transcriptase inhibitor
Zidovudinenucleoside reverse transcriptase inhibitor
Clinical data
Trade namesDuovir-N, Zidovex-LN, others[1]
ATC code
Identifiers
ChemSpider
  • none

The medication is generally well tolerated.[1] Side effects are those of the underlying medications.[2] This includes rash, pancreatitis, low white blood cell levels, and muscle pain.[1] Use is not recommended in those with significant liver problems.[1] Use in pregnancy and breastfeeding appear to be safe.[1] The combination tablet is typically not appropriate for children.[2]

It is on the World Health Organization's List of Essential Medicines.[3] The combination is not commercially available in the United States as of 2018.[4]

See also

References
  1. "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
  2. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.
  3. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.